Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021
Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced it will present new treatment satisfaction data for its oral immunotherapy drug, PALFORZIA, at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 in Poland. The company will share updated treatment satisfaction data evaluated in its Phase 3, randomised, double-blind, placebo-controlled trial, PALISADE, and open-label follow-on trial, ARC004.
Patient-reported treatment satisfaction was evaluated over two years following daily treatment with PALFORZIA in a clinical trial setting using the Treatment Satisfaction Questionnaire for Medication (TSQM-9). Peanut allergic participants reported overall satisfaction with the effectiveness and convenience items, as well as the medication’s ability to treat their condition.
“Patient-centricity is an essential pillar of clinical development, and we look forward to presenting these encouraging patient satisfaction data,” said Andrew Oxtoby, President and Chief Executive Officer of Aimmune Therapeutics. “We know efficacy and safety remain the traditional, crucial endpoints assessed; however, true clinical and medical progress requires a deep understanding of the patient experience – what the patient values and needs for a positive outcome.”
Additional data to be presented at EAACI include an update on the ongoing Phase 3 ARC008 open-label study which is looks at longer-term safety in patients. The data collected by this study will help facilitate discussions around the longer-term safety with clinicians, peanut-allergic individuals, and their families.
Full details of the oral and poster presentations can be found below.
Title: Treatment satisfaction with continued oral immunotherapy for peanut allergy: results after 1, 1.5, and 2 years of daily therapy
Presenter: Katharina Blümchen, MD, University Hospital Frankfurt (Germany)
Session Title: OAS 01 New perspectives in allergen immunotherapy
Date/Time: July 10, 3:05-3:13pmCEST
Title: Longer-term safety outcomes of defatted powder of Arachis hypogaea L. semen (peanuts) in subjects from prior clinical trials (ARC008): a trial-in-progress and preliminary insights
Presenter: Kirsten Beyer, MD, University Hospital Charité (Germany)
Session title: ePoster Allergen Immunotherapy
Date/Time: July 10, 9am-8:30pm CEST
PALFORZIA was approved in December 2020 by the European Commission (EC) for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a peanut-avoidant diet. PALFORZIA may be continued in patients 18 years of age and older.
PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time. PALFORZIA is a rigorously developed, pharmaceutical-grade OIT for peanut allergy with a well-defined allergen profile to assure the consistency of every dose, from 0.5 mg (equivalent to approximately 1/600th of a peanut kernel) to 300 mg.
PALFORZIA is not intended for, and does not provide, immediate relief of allergic symptoms. Therefore, this medicinal product is not to be used for emergency treatment of allergic reactions, including anaphylaxis. Self-injectable adrenaline (epinephrine) must be available to the patient at all times.
Please see full summary of product characteristics at www.aimmune.co.uk/our-product.
Aimmune Therapeutics UK Ltd., a Nestlé Health Science company, is a biopharmaceutical company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases. For more information, please visit www.aimmune.co.uk.
About Nestlé Health Science
Nestlé Health Science (NHSc), a wholly owned subsidiary of Nestlé, is a globally recognised leader in the field of nutritional science. At NHSc we are committed to empowering healthier lives through nutrition for consumers, patients and their healthcare partners. We offer an extensive consumer health portfolio of industry-leading medical nutrition, consumer and vitamins, minerals and supplements (VMS) brands that are science-based solutions covering all facets of health from prevention, to maintenance, all the way through to treatment. NHSc is redefining the way we approach the management of health in several key areas such as pediatric health, allergy, acute care, oncology, metabolic health, healthy aging, gastrointestinal health, and inborn errors of metabolism. Headquartered in Switzerland, NHSc employs over 5,000 people around the world who are committed to making a difference in people's lives, for a healthier today and tomorrow. www.nestlehealthscience.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+44 7940 594788
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Henley & Partners: Investment Migration: “We Need More, Not Less Immigration of People Who Contribute Positively to Society”29.7.2021 10:00:00 CEST | Press release
Henley & Partners Chairman Dr. Christian H. Kaelin says the significant worldwide expansion of investment migration, by which affluent individuals invest in other countries to acquire residence or citizenship, is simply unstoppable. Speaking at The World Ahead Gala Dinnerhosted by The Economist in Athens last week, Dr. Kaelin stated that all over the world countries have realized the importance of residence and citizenship to attract much-needed foreign direct investment, debt-free capital, talented entrepreneurs, and experienced investors. Dr. Kaelin, who is widely considered the pioneer and one of the world’s foremost experts in investment migration, shared the stage with Ireland’s Minister for Finance and President of the Eurogroup, Paschal Donohoe, and Greece’s Minister of Finance, Christos Staikouras, at the annual event to discuss the year ahead with government and business leaders. Further accelerated by the need to alleviate the financial distress following the Covid-19 pandemi
Katherine Alexakis Appointed to Chief Financial Officer of euNetworks29.7.2021 10:00:00 CEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced the appointment of Katherine Alexakis to the leadership team, taking up the role of Chief Financial Officer. This appointment is effective 6 September 2021, at which time Katherine will also join the Board of Directors as an Executive Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005060/en/ Brady Rafuse, CEO of euNetworks (Photo: Business Wire) Katherine joins euNetworks after 15 years working at Goldman Sachs International in London, where she held several roles across the European Equities business. She most recently served as a Managing Director within European Equity Research, sitting on the European Investment Review Committee and leading the European Tactical Research Group. Katherine was also responsible for merchandising the research product across the Securities division. Previously, Katheri
Onera raises €10.5M in Series B funding29.7.2021 10:00:00 CEST | Press release
Onera Health, a leader in sleep diagnostic and monitoring solutions, closed the Series B funding round today, which brought the total funding raised to date above the €24M mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005036/en/ The model is wearing the head and chest patch of Onera STS innovative PSG system. (Photo: Business Wire) Led by Innovation Industries in close collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM and 15th Rock, the company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring products in Europe and the United States. Onera has recently obtained the CE mark for its first product, an innovative polysomnography (PSG) system that brings the gold-standard quality of a hospital diagnostic system directly to a user’s home. “We’re going to leverage the funding to conduct progressively larger s
Prokarium Appoints Uz Stammberger as Chief Medical Officer to Drive Clinical Development in Oncology29.7.2021 10:00:00 CEST | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, today announced the appointment of Uz Stammberger, MD, as Chief Medical Officer. In the role, Dr. Stammberger will lead the advancement of Prokarium’s oncology pipeline into the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005044/en/ Uz Stammberger, MD, Chief Medical Officer of Prokarium (Photo: Business Wire) “Uz brings extensive clinical experience to Prokarium’s team having spent more than two decades in oncology drug development and research,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “We are thrilled to welcome Uz onboard as we expand our clinical portfolio into oncology, and I look forward to working together on the development of our next generation immuno-oncology pipeline.” “Prokarium’s unique technology based on live, attenuated bacteria is a promising and powerful strategy for
BehavioSec Expands Portfolio and Opens Market Access with Another Industry First29.7.2021 09:00:00 CEST | Press release
BehavioSec, industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced that it has extended its patented technology and BehavioSense platform into a SOC/ISO compliant, hosted-version and a cloud-native, SaaS version. These new versions will help more organizations meet compliance and cloud mandates, support frictionless multi-factor authentication (MFA), and gain access to the market’s most advanced behavioral biometrics technology – which until now – has only been employed within the world’s largest banks, e-Identity providers, and online retailers. According to the recent July release of the 2021 Gartner ® Market Guide for Online Fraud Detection, “The convergence between online fraud detection (OFD), identity proofing and authentication continues with many organizations applying OFD capabilities to mitigate risk in identity proofing and authentication events.” The report further adds, “Banks are becoming increasingly comfortable wi
SES Enters Multi-transponder Agreement with NewSpace India Limited via SES-829.7.2021 08:58:00 CEST | Press release
SES announced today that it had entered into a multi-transponder agreement for its SES-8 satellite with NewSpace India Limited (NSIL), a Central Public Sector Enterprise (CPSE) under Department of Space (DoS) based in Bengaluru, India. The nine-transponder capacity agreement on SES-8 at 95 degrees East will be used to support India’s thriving direct-to-home (DTH) market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210728006179/en/ SES Enters Multi-transponder Agreement with NewSpace India Limited via SES-8 (Photo: Business Wire) Deepak Mathur, Executive Vice President of Sales at SES Video, said, “Satellite TV and the programmes it brings hold a very important role for Indian TV viewers. We are honoured to be able to provide continued support and satellite capacity needed to support DTH operations in the country in collaboration with NSIL." Follow us on: Read our Blogs > Visit the Media Gallery > About SES SES has a bold
Mekitec Acquires Grupo Bimbo’s AI-Focused Subsidiary29.7.2021 08:15:00 CEST | Press release
Food quality control system manufacturer Mekitec Group acquired Grupo Bimbo subsidiary Kanan Smart Solution on July 15, 2021, including a software development team and local sales and service operations in Mexico. This solidifies Mekitec’s place among the global leaders of X-ray inspection systems for baking companies and boosts the company’s market position throughout Latin America. Grupo Bimbo has used Mekitec’s X-ray systems, powered by Kanan’s software solutions, for many years. Bimbo Ventures, Grupo Bimbo’s venture arm, will now enable Mekitec to grow faster and increase its focus on baking solutions. In food inspection, X-ray systems are considered the most sustainable choice; they minimize waste and maximize traceability without compromising the main purpose, consumer safety. “Traceability and artificial intelligence are significant drivers for the future of food safety,” says Antti Sivula, Mekitec Group’s CEO. “This acquisition is of major strategic importance for Mekitec, enab